Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia

Maribel Acosta-Tejeda, Héctor Baptista-González, Fany Rosenfeld-Mann, Rocio Trueba-Gómez, Ethel García-Latorre

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), and TAFIa plasma levels are associated with preeclampsia. Materials and Methods: In a case-control study design, we evaluated preeclampsia patients and women with uncomplicated pregnancies. The TAFI polymorphisms were determined by real-time PCR method, and TAFIa plasma levels were established with a chromogenic assay. Results: We included 87 women in each group. The TAFIa levels in the preeclampsia group were 20.4 μg/mL (CI 95% 17.3-23.5), while in the control group, they were significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There were no differences in the genotype distribution or allelic frequency of TAFI polymorphisms between the two groups. In preeclampsia patients and controls heterozygous for the G505A polymorphism, the TAFIa values were 22.8 (16.7-28.9 μg/mL) and 13.2 (11.3-15.0 μg/mL, p 0.019), respectively. In G505A homozygous polymorphism the TAFIa values were 25.7 (18.7-32.6 μg/mL) and 13.5 (1.6-21.9 μg/mL, p 0.041), respectively. In the C1040T and G-438A TAFI wild type polymorphisms, the TAFIa values were 18.3 (12.5-23.9 μg/mL) and 11.5 (9.9-35.0, p 0.033), and 19.4 (10.9-27.9 μg/mL) and 12.5 (10.8-14.2 μg/mL, p 0.006), respectively, without differences in other genotypes. Conclusions: Preeclampsia by itself may be responsible for the increase in TAFIa values rather than the presence of polymorphisms. © 2011 Elsevier Ltd.
Original languageAmerican English
JournalThrombosis Research
DOIs
StatePublished - 1 Oct 2011

Fingerprint

Fibrinolysis
Pre-Eclampsia
Thrombin
Genotype
Case-Control Studies
Real-Time Polymerase Chain Reaction
Pregnancy
Control Groups

Cite this

@article{d0e997e4297e402bbaa3f6b476ef4843,
title = "Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia",
abstract = "Introduction: The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), and TAFIa plasma levels are associated with preeclampsia. Materials and Methods: In a case-control study design, we evaluated preeclampsia patients and women with uncomplicated pregnancies. The TAFI polymorphisms were determined by real-time PCR method, and TAFIa plasma levels were established with a chromogenic assay. Results: We included 87 women in each group. The TAFIa levels in the preeclampsia group were 20.4 μg/mL (CI 95{\%} 17.3-23.5), while in the control group, they were significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There were no differences in the genotype distribution or allelic frequency of TAFI polymorphisms between the two groups. In preeclampsia patients and controls heterozygous for the G505A polymorphism, the TAFIa values were 22.8 (16.7-28.9 μg/mL) and 13.2 (11.3-15.0 μg/mL, p 0.019), respectively. In G505A homozygous polymorphism the TAFIa values were 25.7 (18.7-32.6 μg/mL) and 13.5 (1.6-21.9 μg/mL, p 0.041), respectively. In the C1040T and G-438A TAFI wild type polymorphisms, the TAFIa values were 18.3 (12.5-23.9 μg/mL) and 11.5 (9.9-35.0, p 0.033), and 19.4 (10.9-27.9 μg/mL) and 12.5 (10.8-14.2 μg/mL, p 0.006), respectively, without differences in other genotypes. Conclusions: Preeclampsia by itself may be responsible for the increase in TAFIa values rather than the presence of polymorphisms. {\circledC} 2011 Elsevier Ltd.",
author = "Maribel Acosta-Tejeda and H{\'e}ctor Baptista-Gonz{\'a}lez and Fany Rosenfeld-Mann and Rocio Trueba-G{\'o}mez and Ethel Garc{\'i}a-Latorre",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.thromres.2011.05.019",
language = "American English",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Ltd",

}

Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia. / Acosta-Tejeda, Maribel; Baptista-González, Héctor; Rosenfeld-Mann, Fany; Trueba-Gómez, Rocio; García-Latorre, Ethel.

In: Thrombosis Research, 01.10.2011.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia

AU - Acosta-Tejeda, Maribel

AU - Baptista-González, Héctor

AU - Rosenfeld-Mann, Fany

AU - Trueba-Gómez, Rocio

AU - García-Latorre, Ethel

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Introduction: The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), and TAFIa plasma levels are associated with preeclampsia. Materials and Methods: In a case-control study design, we evaluated preeclampsia patients and women with uncomplicated pregnancies. The TAFI polymorphisms were determined by real-time PCR method, and TAFIa plasma levels were established with a chromogenic assay. Results: We included 87 women in each group. The TAFIa levels in the preeclampsia group were 20.4 μg/mL (CI 95% 17.3-23.5), while in the control group, they were significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There were no differences in the genotype distribution or allelic frequency of TAFI polymorphisms between the two groups. In preeclampsia patients and controls heterozygous for the G505A polymorphism, the TAFIa values were 22.8 (16.7-28.9 μg/mL) and 13.2 (11.3-15.0 μg/mL, p 0.019), respectively. In G505A homozygous polymorphism the TAFIa values were 25.7 (18.7-32.6 μg/mL) and 13.5 (1.6-21.9 μg/mL, p 0.041), respectively. In the C1040T and G-438A TAFI wild type polymorphisms, the TAFIa values were 18.3 (12.5-23.9 μg/mL) and 11.5 (9.9-35.0, p 0.033), and 19.4 (10.9-27.9 μg/mL) and 12.5 (10.8-14.2 μg/mL, p 0.006), respectively, without differences in other genotypes. Conclusions: Preeclampsia by itself may be responsible for the increase in TAFIa values rather than the presence of polymorphisms. © 2011 Elsevier Ltd.

AB - Introduction: The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), and TAFIa plasma levels are associated with preeclampsia. Materials and Methods: In a case-control study design, we evaluated preeclampsia patients and women with uncomplicated pregnancies. The TAFI polymorphisms were determined by real-time PCR method, and TAFIa plasma levels were established with a chromogenic assay. Results: We included 87 women in each group. The TAFIa levels in the preeclampsia group were 20.4 μg/mL (CI 95% 17.3-23.5), while in the control group, they were significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There were no differences in the genotype distribution or allelic frequency of TAFI polymorphisms between the two groups. In preeclampsia patients and controls heterozygous for the G505A polymorphism, the TAFIa values were 22.8 (16.7-28.9 μg/mL) and 13.2 (11.3-15.0 μg/mL, p 0.019), respectively. In G505A homozygous polymorphism the TAFIa values were 25.7 (18.7-32.6 μg/mL) and 13.5 (1.6-21.9 μg/mL, p 0.041), respectively. In the C1040T and G-438A TAFI wild type polymorphisms, the TAFIa values were 18.3 (12.5-23.9 μg/mL) and 11.5 (9.9-35.0, p 0.033), and 19.4 (10.9-27.9 μg/mL) and 12.5 (10.8-14.2 μg/mL, p 0.006), respectively, without differences in other genotypes. Conclusions: Preeclampsia by itself may be responsible for the increase in TAFIa values rather than the presence of polymorphisms. © 2011 Elsevier Ltd.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80054930072&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=80054930072&origin=inward

U2 - 10.1016/j.thromres.2011.05.019

DO - 10.1016/j.thromres.2011.05.019

M3 - Article

C2 - 21708401

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -